HMBD 011
Alternative Names: HMBD-011Latest Information Update: 30 Jun 2023
At a glance
- Originator Hummingbird Bioscience
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer
Most Recent Events
- 08 May 2023 Preclinical trials in Autoimmune disorders in Singapore (Parenteral), prior to May 2023
- 08 May 2023 Preclinical trials in Cancer in Singapore (Parenteral), prior to May 2023
- 08 May 2023 Pharmacodynamics data from a preclinical study in Autoimmune Disorders released by Hummingbird Bioscience